Clinical Scorecard: Efficacy of Glofitamab in Sequential Treatment Approaches for Relapsed/Refractory B-Cell Lymphoma: Insights from a Single-Center Real-World Analysis
At a Glance
Category
Detail
Condition
Relapsed/Refractory B-Cell Lymphoma
Key Mechanisms
Glofitamab is a bispecific antibody targeting CD20 and CD3, providing a novel immunotherapy approach.
Target Population
Adults (≥18 years) with relapsed/refractory B-cell lymphoma, including DLBCL, DLBCL-RT, and Burkitt lymphoma.
Care Setting
Single-center retrospective cohort study
Key Highlights
Glofitamab shows efficacy as rescue therapy after CAR-T therapy failure.
Demonstrated durable anti-tumor activity in various treatment sequences.
Cytokine release syndrome (CRS) occurred in 44% of patients, mostly low-grade.
Guideline-Based Recommendations
Diagnosis
Patients must have a pathological diagnosis of relapsed/refractory B-cell lymphoma.
Management
Glofitamab can be used as rescue therapy, bridging therapy, or monotherapy.
Monitoring & Follow-up
Monitor for adverse events, particularly cytokine release syndrome.
Risks
Potential for low-grade CRS and other treatment-related adverse events.
Patient & Prescribing Data
24 adult patients treated with Glofitamab between September 2024 and December 2025.
Patients received Glofitamab following a step-up dosing regimen.
Clinical Best Practices
Consider Glofitamab as a sequential treatment option for r/r B-cell lymphoma.
Utilize Glofitamab as a bridging therapy to CAR-T infusion when appropriate.
